Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The study evaluated the long-term safety of Desvenlafaxine Succinate (DVS) Slow Release (SR)
during open-label treatment in adult outpatients who had a primary diagnosis of major
depressive disorder (MDD). The study also evaluated the long-term response of subjects
receiving DVS SR for clinical global evaluation, functionality, general well-being, pain, and
absence of depressive symptoms (remission).